KRAS and neoplasm: Treatment of the KRAS-mutant mixed cultures with cetuximab or trametinib alone reduced tumor take rate (determined on day 38 post-injection) and substantially prolonged the period required for achieving an equal 1.0 cm3 tumor mass in two out of three tumors (Fig 7E and 7F).